Mid-term Outcomes of Percutaneous Pulmonary Valve Replacement with Edwards-Sapien Bioprosthesis in Native Right Ventricular Outflow Tract

Overview

Journal Sci Rep

Date 2025 Feb 1

PMID 39893235

Authors

Yassin Belahnech

Gerard Marti-Aguasca

Laura Dos-Subira

Pedro Betrian-Blasco

Bruno Garcia Del Blanco

Maria Calvo-Barcelo

Eduard Rodenas-Alesina

Antonia Pijuan-Domenech

Ferran Gran

Queralt Ferrer

Gemma Giralt-Garcia

Berta Miranda

Blanca Gordon

Victor Gonzalez-Fernandez

Jose A Barrabes

Ferran Roses-Noguer

Ignacio Ferreira-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40.8%) and non-native (59.2%) RVOTs. The primary endpoint was a composite of endocarditis, reinterventions, and cardiovascular death and secondary outcomes included prosthetic valve dysfunction (PVD), tricuspid regurgitation (TR), right ventricular ejection fraction (RVEF), and indexed ventricular volumes. The median patient age was 23.9 years. Pulmonary regurgitation was predominant in the native RVOT group (67.7%), while pulmonary stenosis or combined lesions were more common in the non-native group (90.9%). Procedural success was 98.7%. After a median follow-up of 3.3 years, there was no significant difference in freedom from the primary outcome between groups (87.1% native vs. 93.1% non-native, p = 0.875). Endocarditis and reinterventions occurred at 1.2 per 100 patient-years, and PVD at 3.19 per 100 patient-years, with no differences between groups. A 1-year reduction in ventricular volumes and TR was seen only in the non-native group, with no improvement in RVEF. Overall, PPVR with the ES valve demonstrates satisfactory mid-term outcomes in both native and non-native RVOTs.

References

Megaly M, Han K, Sedhom R, Aboulhosn J, Moga F, Mudy K . Outcomes of Percutaneous and Surgical Pulmonary Valve Implantation. Cardiovasc Revasc Med. 2021; 32:27-32. DOI: 10.1016/j.carrev.2020.12.035. View

McElhinney D, Zhang Y, Aboulhosn J, Morray B, Biernacka E, Qureshi A . Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement. J Am Coll Cardiol. 2021; 78(6):575-589. DOI: 10.1016/j.jacc.2021.05.044. View

Georgiev S, Ewert P, Eicken A, Hager A, Horer J, Cleuziou J . Munich Comparative Study: Prospective Long-Term Outcome of the Transcatheter Melody Valve Versus Surgical Pulmonary Bioprosthesis With Up to 12 Years of Follow-Up. Circ Cardiovasc Interv. 2020; 13(7):e008963. DOI: 10.1161/CIRCINTERVENTIONS.119.008963. View

Shahanavaz S, Asnes J, Grohmann J, Qureshi A, Rome J, Tanase D . Intentional Fracture of Bioprosthetic Valve Frames in Patients Undergoing Valve-in-Valve Transcatheter Pulmonary Valve Replacement. Circ Cardiovasc Interv. 2018; 11(8):e006453. DOI: 10.1161/CIRCINTERVENTIONS.118.006453. View

Cheatham J, Hellenbrand W, Zahn E, Jones T, Berman D, Vincent J . Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation. 2015; 131(22):1960-70. DOI: 10.1161/CIRCULATIONAHA.114.013588. View

Lehner A, Haas N, Dietl M, Jakob A, Schulze-Neick I, Dalla Pozza R . The risk of infective endocarditis following interventional pulmonary valve implantation: A meta-analysis. J Cardiol. 2019; 74(3):197-205. DOI: 10.1016/j.jjcc.2019.04.007. View

Kenny D, Rhodes J, Fleming G, Kar S, Zahn E, Vincent J . 3-Year Outcomes of the Edwards SAPIEN Transcatheter Heart Valve for Conduit Failure in the Pulmonary Position From the COMPASSION Multicenter Clinical Trial. JACC Cardiovasc Interv. 2018; 11(19):1920-1929. DOI: 10.1016/j.jcin.2018.06.001. View

Sinha S, Aboulhosn J, Asnes J, Bocks M, Zahn E, Goldstein B . Initial results from the off-label use of the SAPIEN S3 valve for percutaneous transcatheter pulmonary valve replacement: A multi-institutional experience. Catheter Cardiovasc Interv. 2018; 93(3):455-463. DOI: 10.1002/ccd.27973. View

Baumgartner H, De Backer J, Babu-Narayan S, Budts W, Chessa M, Diller G . 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020; 42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. View

10.

Alvarez-Fuente M, Garrido-Lestache E, Fernandez-Pineda L, Romera B, Sanchez I, Centella T . Timing of Pulmonary Valve Replacement: How Much Can the Right Ventricle Dilate Before it Looses Its Remodeling Potential?. Pediatr Cardiol. 2015; 37(3):601-5. DOI: 10.1007/s00246-015-1320-4. View

11.

Jones T, McElhinney D, Vincent J, Hellenbrand W, Cheatham J, Berman D . Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial. Circ Cardiovasc Interv. 2021; 15(1):e010852. PMC: 8765216. DOI: 10.1161/CIRCINTERVENTIONS.121.010852. View

12.

Bergersen L, Benson L, Gillespie M, Cheatham S, Crean A, Hor K . Harmony Feasibility Trial: Acute and Short-Term Outcomes With a Self-Expanding Transcatheter Pulmonary Valve. JACC Cardiovasc Interv. 2017; 10(17):1763-1773. DOI: 10.1016/j.jcin.2017.05.034. View

13.

Plessis J, Hascoet S, Baruteau A, Godart F, Le Gloan L, Warin Fresse K . Edwards SAPIEN Transcatheter Pulmonary Valve Implantation: Results From a French Registry. JACC Cardiovasc Interv. 2018; 11(19):1909-1916. DOI: 10.1016/j.jcin.2018.05.050. View

14.

Hoffman J . Congenital heart disease: incidence and inheritance. Pediatr Clin North Am. 1990; 37(1):25-43. DOI: 10.1016/s0031-3955(16)36830-4. View

15.

Van den Eynde J, Sa M, Vervoort D, Roever L, Meyns B, Budts W . Pulmonary Valve Replacement in Tetralogy of Fallot: An Updated Meta-Analysis. Ann Thorac Surg. 2020; 113(3):1036-1046. DOI: 10.1016/j.athoracsur.2020.11.040. View

16.

Jones T, Rome J, Armstrong A, Berger F, Hellenbrand W, Cabalka A . Transcatheter Pulmonary Valve Replacement Reduces Tricuspid Regurgitation in Patients With Right Ventricular Volume/Pressure Overload. J Am Coll Cardiol. 2016; 68(14):1525-35. DOI: 10.1016/j.jacc.2016.07.734. View

17.

Hascoet S, Mauri L, Claude C, Fournier E, Lourtet J, Riou J . Infective Endocarditis Risk After Percutaneous Pulmonary Valve Implantation With the Melody and Sapien Valves. JACC Cardiovasc Interv. 2017; 10(5):510-517. DOI: 10.1016/j.jcin.2016.12.012. View

18.

Bokma J, Geva T, Sleeper L, Lee J, Lu M, Sompolinsky T . Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot. J Am Coll Cardiol. 2023; 81(21):2075-2085. DOI: 10.1016/j.jacc.2023.02.052. View

19.

Wilson W, Benson L, Osten M, Shah A, Horlick E . Transcatheter Pulmonary Valve Replacement With the Edwards Sapien System: The Toronto Experience. JACC Cardiovasc Interv. 2016; 8(14):1819-27. DOI: 10.1016/j.jcin.2015.08.016. View

20.

McElhinney D, Cheatham J, Jones T, Lock J, Vincent J, Zahn E . Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv. 2011; 4(6):602-14. DOI: 10.1161/CIRCINTERVENTIONS.111.965616. View